November 11, 2025

SPT Labtech and Alithea Genomics Collaborate to Automate Ultra Sensitive Single-Cell Transcriptomic Workflows

SPT Labtech and Alithea Genomics Collaborate to Automate Ultra Sensitive Single-Cell Transcriptomic Workflows

Cambridge, UK, and Lausanne, Switzerland, 05 November 2025: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and Alithea Genomics, a pioneer in the field of large-scale RNA sequencing and transcriptomics, today announced a collaboration to provide an automated solution for single-cell transcriptomics. 

The collaboration integrates Alithea Genomics’ ultra-sensitive single-cell RNA-seq technology, MERCURIUS FLASH-seq, with SPT Labtech’s firefly® liquid handling platform, creating a scalable and reproducible workflow for transcriptomics research. The automated workflow is immediately available to customers worldwide through SPT Labtech and Alithea Genomics’ application support teams.

Single-cell transcriptomics is a rapidly expanding field driving advances in cell biology, immunology, and drug discovery. However, many workflows remain limited by manual library preparation steps, which can introduce variability and constrain throughput. This collaboration directly addresses that bottleneck by combining firefly’s low-volume precision dispensing with Alithea Genomics’ scalable RNA-sequencing chemistry, improving reproducibility, throughput, and accessibility for single-cell studies. As demand for higher-throughput, cost-efficient single-cell sequencing grows, the ability to automate sensitive RNA-seq protocols is becoming essential for both academic and research environments.

Alithea Genomics has gained recognition for transforming RNA sequencing with its scalable and cost-effective solutions. MERCURIUS FLASH-seq, a novel single-cell RNA-seq protocol, offers gene detection sensitivity on ultra-low input samples and single-cells. 

Riccardo Dainese, CEO and co-founder of Alithea Genomics, said: “Our mission has always been to make high-throughput and high-quality RNA-seq accessible and scalable for any lab. By combining MERCURIUS FLASH-seq and MERCURIUS Total DRUG-seq with SPT Labtech’s firefly, we’re removing key bottlenecks in library preparation workflows. This partnership simplifies complex processes, drives down costs, and empowers researchers to focus on discovery.”

Morten Frost, Chief Commercial Officer at SPT Labtech, commented: “This collaboration represents a step toward broader automation of complex RNA workflows, supporting the growing integration of transcriptomics into translational and clinical research. Implementing this workflow on firefly, laboratories can achieve a new level of efficiency, reproducibility, and throughput. The modular architecture of firefly supports both discovery-scale and large-scale experimental designs, enabling consistent results across varied throughput needs.”

For more information and to hear directly from experts at Alithea Genomics and SPT Labtech, see details of the upcoming webinar on 10 November, 16:00 GMT: Automating RNA-seq library prep: From rare cells scRNA-seq to high-throughput bulk RNA-seq. 

Media Contact: Dr Ben Rutter, Zyme Communicationsben.rutter@zymecommunications.com

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp